MKI67 and breast cancer: In our future studies, external validation in large clinical populations will be necessary, and we would also like to integrate additional factors, such as lymph node metastasis, Ki67 expression, molecular subtypes of breast cancer, and progression-free survival to determine the microbiome associated with breast cancer prognosis.